Isamu Okamoto

List of Publications by Year
in descending order

196	14,365	87843 38	21521 114
papers	citations	h-index	g-index

197	197	197	12488
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncology, The, 2010, 11, 121-128.	5.1	3,794
2	Osimertinib in UntreatedEGFR-Mutated Advanced Nonâ€“Small-Cell Lung Cancer. New England Journal of Medicine, 2018, 378, 113-125.	13.9	3,530
3	Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study. Lancet Oncology, The, 2014, 15, 1236-1244.	5.1	678
4	Weekly nab-Paclitaxel in Combination With Carboplatin Versus Solvent-Based Paclitaxel Plus Carboplatin as First-Line Therapy in Patients With Advanced Nonâ€“Small-Cell Lung Cancer: Final Results of a Phase III Trial. Journal of Clinical Oncology, 2012, 30, 2055-2062.	0.8	676
5	CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2018, 36, 3290-3297.	0.8	515
6	A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous NSCLC: Protocol-Specified Final Analysis of KEYNOTE-407. Journal of Thoracic Oncology, 2020, 15, 1657-1669.	0.5	395
7	Induction of PD-L1 Expression by the EML4â€“ALK Oncoprotein and Downstream Signaling Pathways in Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2015, 21, 4014-4021.	3.2	392
8	Phase III Trial Comparing Oral S-1 Plus Carboplatin With Paclitaxel Plus Carboplatin in Chemotherapy-NaÃ¯ve Patients With Advanced Nonâ€“Small-Cell Lung Cancer: Results of a West Japan Oncology Group Study. Journal of Clinical Oncology, 2010, 28, 5240-5246.	0.8	161
9	Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer. Lung Cancer, 2015, 88, 74-79.	0.9	157
10	Re-biopsy status among non-small cell lung cancer patients in Japan: A retrospective study. Lung Cancer, 2016, 101, 1-8.	0.9	118
11	Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC: Results From the Phase 3 TAHOE Study. Journal of Thoracic Oncology, 2021, 16, 1547-1558.	0.5	108
12	Osimertinib versus standard-of-care EGFR-TKI as first-line treatment for EGFRm advanced NSCLC: FLAURA Japanese subset. Japanese Journal of Clinical Oncology, 2019, 49, 29-36.	0.6	101
13	Tissue and Plasma EGFR Mutation Analysis in the FLAURA Trial: Osimertinib versus Comparator EGFR Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with EGFR-Mutated Advanced Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2019, 25, 6644-6652.	3.2	100
14	Osimertinib versus Standard of Care EGFR TKI as First-Line Treatment in Patients with EGFRm Advanced NSCLC: FLAURA Asian Subset. Journal of Thoracic Oncology, 2019, 14, 99-106.	0.5	82
15	PD-L1 expression in lung adenocarcinoma harboring EGFR mutations or ALK rearrangements. Lung Cancer, 2018, 118, 36-40.	0.9	81
16	Randomized Phase III Study of Pemetrexed Plus Cisplatin Versus Vinorelbine Plus Cisplatin for Completely Resected Stage II to IIIA Nonsquamous Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2020, 38, 2187-2196.	0.8	78
17	Prevalence of Delta-like protein 3 expression in patients with small cell lung cancer. Lung Cancer, 2018, 115, 116-120.	0.9	76
18	Digital PCR analysis of plasma cell-free DNA for non-invasive detection of drug resistance mechanisms in EGFR mutant NSCLC: Correlation with paired tumor samples. Oncotarget, 2015, 6, 30850-30858.	0.8	72

#	Article	IF	Citations
19	Rovalpituzumab Tesirine as a Maintenance Therapy After First-Line Platinum-Based Chemotherapy in Patients With Extensive-Stageâ€“SCLC: Results From the Phase 3 MERU Study. Journal of Thoracic Oncology, 2021, 16, 1570-1581.	0.5	65
20	Acquisition of the T790M resistance mutation during afatinib treatment in EGFR tyrosine kinase inhibitor-naÃ¯ve patients with nonâ€“small cell lung cancer harboring EGFR mutations. Oncotarget, 2017, 8, 68123-68130.	0.8	63
21	Real world treatment and outcomes in EGFR mutation-positive non-small cell lung cancer: Long-term follow-up of a large patient cohort. Lung Cancer, 2018, 117, 14-19.	0.9	63
22	The anti-HER3 antibody patritumab abrogates cetuximab resistance mediated by heregulin in colorectal cancer cells. Oncotarget, 2014, 5, 11847-11856.	0.8	61
23	Randomized Phase III Study of Gefitinib Versus Cisplatin Plus Vinorelbine for Patients With Resected Stage II-IIIA Nonâ€“Small-Cell Lung Cancer With EGFR Mutation (IMPACT). Journal of Clinical Oncology, 2022, 40, 231-241.	0.8	61
24	Molecular Detection of Cancer Cells by Competitive Reverse Transcription-Polymerase Chain Reaction Analysis of Specific CD44 Variant RNAs. Journal of the National Cancer Institute, 1998, 90, 307-315.	3.0	60
25	Serum markers associated with treatment response and survival in non-small cell lung cancer patients treated with anti-PD-1 therapy. Lung Cancer, 2020, 145, 18-26.	0.9	57
26	Phase 3 Trial Comparing Nanoparticle Albumin-Bound Paclitaxel With Docetaxel for Previously Treated Advanced NSCLC. Journal of Thoracic Oncology, 2021, 16, 1523-1532.	0.5	57
27	Real-world effectiveness and safety of nivolumab in patients with non-small cell lung cancer: A multicenter retrospective observational study in Japan. Lung Cancer, 2020, 140, 8-18.	0.9	56
28	Characteristics and overall survival of EGFR mutation-positive non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors: a retrospective analysis for 1660 Japanese patients. Japanese Journal of Clinical Oncology, 2016, 46, 462-467.	0.6	54
29	Osimertinib in Japanese patients with <scp>EGFR</scp> T790M mutationâ€positive advanced nonâ€smallâ€cell lung cancer: <scp>AURA</scp>3 trial. Cancer Science, 2018, 109, 1930-1938.	1.7	53
30	Erlotinib plus bevacizumab (EB) versus erlotinib alone (E) as first-line treatment for advanced EGFR mutationâ€“positive non-squamous nonâ€“small-cell lung cancer (NSCLC): Survival follow-up results of JO25567.. Journal of Clinical Oncology, 2018, 36, 9007-9007.	0.8	53
31	A Phase 2 Study of Atezolizumab for Pretreated NSCLC With Idiopathic Interstitial Pneumonitis. Journal of Thoracic Oncology, 2020, 15, 1935-1942.	0.5	50
32	Erlotinib Plus Bevacizumab Phase II Study in Patients with Advanced Non-small-Cell Lung Cancer (JO25567): Updated Safety Results. Drug Safety, 2018, 41, 229-237.	1.4	48
33	Comparison of Carboplatin Plus Pemetrexed Followed by Maintenance Pemetrexed With Docetaxel Monotherapy in Elderly Patients With Advanced Nonsquamous Nonâ€“Small Cell Lung Cancer. JAMA Oncology, 2020, 6, e196828.	3.4	48
34	Treatment Rationale and Design for J-SONIC: AÂRandomized Study of Carboplatin Plus Nab-paclitaxel With or Without Nintedanib for Advanced Nonâ€“Small-cell Lung Cancer With Idiopathic Pulmonary Fibrosis. Clinical Lung Cancer, 2018, 19, e5-e9.	1.1	44
35	Safety and efficacy of PD-1 inhibitors in nonâ€“small cell lung cancer patients positive for antinuclear antibodies. Lung Cancer, 2019, 130, 5-9.	0.9	44
36	Alectinib for Patients with ALK Rearrangementâ€“Positive Nonâ€“Small Cell Lung Cancer and a Poor Performance Status (Lung Oncology Group in KyushuÂ1401). Journal of Thoracic Oncology, 2017, 12, 1161-1166.	0.5	42

#	Article	IF	Citations
37	Clinical impact of skeletal muscle area in patients with non-small cell lung cancer treated with anti-PD-1 inhibitors. Journal of Cancer Research and Clinical Oncology, 2020, 146, 1217-1225.	1.2	42
38	Association of preoperative serum CRP with PD-L1 expression in 508 patients with non-small cell lung cancer: A comprehensive analysis of systemic inflammatory markers. Surgical Oncology, 2018, 27, 88-94.	0.8	41
39	Phase I study of salazosulfapyridine in combination with cisplatin and pemetrexed for advanced nonâ€smallâ€cell lung cancer. Cancer Science, 2017, 108, 1843-1849.	1.7	40
40	18F-FDG uptake in PET/CT is a potential predictive biomarker of response to anti-PD-1 antibody therapy in non-small cell lung cancer. Scientific Reports, 2019, 9, 13362.	1.6	39
41	Early clearance of plasma EGFR mutations as a predictor of response to osimertinib and comparator EGFR-TKIs in the FLAURA trial.. Journal of Clinical Oncology, 2019, 37, 9020-9020.	0.8	39
42	Continuous monitoring of neutrophils to lymphocytes ratio for estimating the onset, severity, and subsequent prognosis of immune related adverse events. Scientific Reports, 2021, 11, 1324.	1.6	38
43	Phase II study of erlotinib plus tivantinib (ARQ 197) in patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer just after progression on EGFR-TKI, gefitinib or erlotinib. ESMO Open, 2016, 1, e000063.	2.0	37
44	MET-targeted therapy for gastric cancer: the importance of a biomarker-based strategy. Gastric Cancer, 2016, 19, 687-695.	2.7	37
45	Most T790M mutations are present on the same EGFR allele as activating mutations in patients with nonâ€“small cell lung cancer. Lung Cancer, 2017, 108, 75-82.	0.9	37
46	The CLIP1â€“LTK fusion is an oncogenic driverÂin nonâ€smallâ€cell lung cancer. Nature, 2021, 600, 319-323.	13.7	37
47	Summary of the Japanese Respiratory Society statement for the treatment of lung cancer with comorbid interstitial pneumonia. Respiratory Investigation, 2019, 57, 512-533.	0.9	36
48	Final overall survival results of WJTOG 3405, a randomized phase 3 trial comparing gefitinib (G) with cisplatin plus docetaxel (CD) as the first-line treatment for patients with non-small cell lung cancer (NSCLC) harboring mutations of the epidermal growth factor receptor (EGFR).. Journal of Clinical Oncology, 2014, 32, 8117-8117.	0.8	36
49	Bevacizumab beyond disease progression after firstâ€line treatment with bevacizumab plus chemotherapy in advanced nonsquamous nonâ€“small cell lung cancer (<scp>W</scp>est) Tj ETQq1 1 0.784314 rgBT /Overlock 10 T trial. Cancer, 2016, 122, 1050-1059.	2.0	35
50	Design and Rationale for a Phase III, Randomized, Placebo-controlled Trial of Durvalumab With or Without Tremelimumab After Concurrent Chemoradiotherapy for Patients With Limited-stage Small-cell Lung Cancer: The ADRIATIC Study. Clinical Lung Cancer, 2020, 21, e84-e88.	1.1	35
51	Clinical utility of pretreatment Glasgow prognostic score in non-small-cell lung cancer patients treated with immune checkpoint inhibitors. Lung Cancer, 2021, 152, 27-33.	0.9	35
52	Clinical impact of probiotics on the efficacy of <scp>antiâ€PD</scp>â€1 monotherapy in patients with nonsmall cell lung cancer: A multicenter retrospective survival analysis study with inverse probability of treatment weighting. International Journal of Cancer, 2021, 149, 473-482.	2.3	35
53	Nintedanib plus chemotherapy for nonsmall cell lung cancer with idiopathic pulmonary fibrosis: a randomised phase 3 trial. European Respiratory Journal, 2022, 60, 2200380.	3.1	34
54	Multiplex genomic profiling of non-small cell lung cancers from the LETS phase III trial of first-line S-1/carboplatin versus paclitaxel/carboplatin: results of a West Japan Oncology Group study. Oncotarget, 2014, 5, 2293-2304.	0.8	32

#	Article	IF	Citations
55	Highly sensitive and quantitative evaluation of the EGFR T790M mutation by nanofluidic digital PCR. Oncotarget, 2015, 6, 20466-20473.	0.8	32
56	<scp>FGFR</scp> gene alterations in lung squamous cell carcinoma are potential targets for the multikinase inhibitor nintedanib. Cancer Science, 2016, 107, 1667-1676.	1.7	31
57	Biomarker-Directed Phase II Platform Study in Patients With EGFR Sensitizing Mutation-Positive Advanced/Metastatic Non-Small Cell Lung Cancer Whose Disease Has Progressed on First-Line Osimertinib Therapy (ORCHARD). Clinical Lung Cancer, 2021, 22, 601-606.	1.1	31
58	Single-Cell Analyses Reveal Diverse Mechanisms of Resistance to EGFR Tyrosine Kinase Inhibitors in Lung Cancer. Cancer Research, 2021, 81, 4835-4848.	0.4	31
59	Realâ€world data on NGS using the Oncomine DxTT for detecting genetic alterations in nonâ€smallâ€cell lung cancer: WJOG13019L. Cancer Science, 2022, 113, 221-228.	1.7	31
60	Nicotine induces resistance to erlotinib via cross-talk between Î± 1 nAChR and EGFR in the non-small cell lung cancer xenograft model. Lung Cancer, 2015, 88, 1-8.	0.9	30
61	Osimertinib versus osimertinib plus chemotherapy for nonâ€“small cell lung cancer with EGFR (T790M)-associated resistance to initial EGFR inhibitor treatment: An open-label, randomised phase 2 clinical trial. European Journal of Cancer, 2021, 149, 14-22.	1.3	30
62	Discrepancy in Programmed Cell Death-Ligand 1 Between Primary and Metastatic Non-small Cell Lung Cancer. Anticancer Research, 2017, 37, 4223-4228.	0.5	30
63	Trastuzumab emtansine for patients with nonâ€“small cell lung cancer positive for human epidermal growth factor receptor 2 exon-20 insertion mutations. European Journal of Cancer, 2022, 162, 99-106.	1.3	30
64	Phase II trial of weekly nab-paclitaxel for previously treated advanced nonâ€“small cell lung cancer: Kumamoto thoracic oncology study group (KTOSG) trial 1301. Lung Cancer, 2016, 99, 41-45.	0.9	28
65	Randomized Phase III Study of Continuation Maintenance Bevacizumab With or Without Pemetrexed in Advanced Nonsquamous Nonâ€“Small-Cell Lung Cancer: COMPASS (WJOG5610L). Journal of Clinical Oncology, 2020, 38, 793-803.	0.8	28
66	Intrinsic and Extrinsic Regulation of PD-L2 Expression in Oncogene-Driven Nonâ€“Small Cell Lung Cancer. Journal of Thoracic Oncology, 2018, 13, 926-937.	0.5	27
67	Exploration of resistance mechanisms for epidermal growth factor receptorâ€tyrosine kinase inhibitors based on plasma analysis by digital polymerase chain reaction and nextâ€generation sequencing. Cancer Science, 2018, 109, 3921-3933.	1.7	27
68	Phase 3 study of ceritinib vs chemotherapy in ALK-rearranged NSCLC patients previously treated with chemotherapy and crizotinib (ASCEND-5): Japanese subset. Japanese Journal of Clinical Oncology, 2018, 48, 367-375.	0.6	26
69	Subgroup Analysis of Japanese Patients in a Phase III Study of Atezolizumab in Extensive-stage Small-cell Lung Cancer (IMpower133). Clinical Lung Cancer, 2019, 20, 469-476.e1.	1.1	26
70	First-line afatinib for the treatment of EGFR mutation-positive non-small-cell lung cancer in the â€˜real-worldâ€™ clinical setting. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591983637.	1.4	25
71	Prognostic Impact of Programmed Death-Ligand 2 Expression in Primary Lung Adenocarcinoma Patients. Annals of Surgical Oncology, 2019, 26, 1916-1924.	0.7	25
72	Heterogeneity of Anaplastic Lymphoma Kinase Gene Rearrangement in Nonâ€“Small-Cell Lung Carcinomas: A Comparative Study Between Small Biopsy and Excision Samples. Journal of Thoracic Oncology, 2015, 10, 800-805.	0.5	24

#	Article	IF	Citations
73	Bilateral ovarian metastasis of non-small cell lung cancer with ALK rearrangement. Lung Cancer, 2014, 83, 302-304.	0.9	23
74	Expression of brain-derived neurotrophic factor and its receptor TrkB is associated with poor prognosis and a malignant phenotype in small cell lung cancer. Lung Cancer, 2018, 120, 98-107.	0.9	23
75	A Clinicopathological and Prognostic Analysis of PD-L2 Expression in Surgically Resected Primary Lung Squamous Cell Carcinoma. Annals of Surgical Oncology, 2019, 26, 1925-1933.	0.7	23
76	Development of anaplastic lymphoma kinase (ALK) inhibitors and molecular diagnosis in ALK rearrangement-positive lung cancer. OncoTargets and Therapy, 2014, 7, 375.	1.0	22
77	Marked response to pembrolizumab in a patient with pulmonary pleomorphic carcinoma highly positive for PD-L1. Lung Cancer, 2017, 112, 230-231.	0.9	22
78	Osimertinib for Japanese patients with T790Mâ€positive advanced nonâ€smallâ€cell lung cancer: A pooled subgroup analysis. Cancer Science, 2019, 110, 2884-2893.	1.7	22
79	A Japanese lung cancer registry study on demographics and treatment modalities in medically treated patients. Cancer Science, 2020, 111, 1685-1691.	1.7	22
80	Phase II study of atezolizumab with bevacizumab for non-squamous non-small cell lung cancer with high PD-L1 expression (@Be Study). , 2022, 10, e004025.		22
81	NEUROD1 is highly expressed in extensive-disease small cell lung cancer and promotes tumor cell migration. Lung Cancer, 2020, 146, 97-104.	0.9	21
82	Randomized, Double-Blind, Phase III Study of Fosnetupitant Versus Fosaprepitant for Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: CONSOLE. Journal of Clinical Oncology, 2022, 40, 180-188.	0.8	21
83	Longitudinal monitoring of somatic genetic alterations in circulating cellâ€free DNA during treatment with epidermal growth factor receptorâ€“tyrosine kinase inhibitors. Cancer, 2020, 126, 219-227.	2.0	20
84	Clinical Significance of PD-L1 Expression in Brain Metastases from Non-small Cell Lung Cancer. Anticancer Research, 2018, 38, 553-557.	0.5	19
85	Phase I safety and pharmacokinetics study of rovalpituzumab tesirine in Japanese patients with advanced, recurrent small cell lung cancer. Lung Cancer, 2019, 135, 145-150.	0.9	18
86	Clinical significance of monitoring EGFR mutation in plasma using multiplexed digital PCR in EGFR mutated patients treated with afatinib (West Japan Oncology Group 8114LTR study). Lung Cancer, 2019, 131, 128-133.	0.9	18
87	Plasma screening for the T790M mutation of EGFR and phase 2 study of osimertinib efficacy in plasma T790Mâ€positive nonâ€small cell lung cancer: West Japan Oncology Group 8815L/LPS study. Cancer, 2020, 126, 1940-1948.	2.0	18
88	Immune-checkpoint profiles for T cells in bronchoalveolar lavage fluid of patients with immune-checkpoint inhibitor-related interstitial lung disease. International Immunology, 2020, 32, 547-557.	1.8	18
89	Detection of identical T cell clones in peritumoral pleural effusion and pneumonitis lesions in a cancer patient during immune-checkpoint blockade. Oncotarget, 2018, 9, 30587-30593.	0.8	18
90	Anticancer drug treatment for advanced lung cancer with interstitial lung disease. Respiratory Investigation, 2018, 56, 307-311.	0.9	17

#	Article	IF	Citations
91	PD-L2 Expression as a Potential Predictive Biomarker for the Response to Anti-PD-1 Drugs in Patients with Non-small Cell Lung Cancer. Anticancer Research, 2018, 38, 5897-5901.	0.5	17
92	Durable response to nivolumab in a lung adenocarcinoma patient with idiopathic pulmonary fibrosis. Thoracic Cancer, 2018, 9, 1519-1521.	0.8	17
93	Prognostic significance of pre-treatment ALBI grade in advanced non-small cell lung cancer receiving immune checkpoint therapy. Scientific Reports, 2021, 11, 15057.	1.6	17
94	A Juvenile Case of Pulmonary Lymphangitic Carcinomatosis Caused by Sigmoid Colon Cancer with a Component of Micropapillary Carcinoma. Internal Medicine, 2011, 50, 2361-2365.	0.3	16
95	Severe acute interstitial lung disease in a patient with anaplastic lymphoma kinase rearrangementâ€“positive nonâ€“small cell lung cancer treated with alectinib. Investigational New Drugs, 2015, 33, 1148-1150.	1.2	16
96	Heterogeneous distribution of alectinib in neuroblastoma xenografts revealed by matrixâ€assisted laser desorption ionization mass spectrometry imaging: a pilot study. British Journal of Pharmacology, 2018, 175, 29-37.	2.7	16
97	Genetic Profiling of Non-Small Cell Lung Cancer at Development of Resistance to First- or Second-Generation EGFR-TKIs by CAPP-Seq Analysis of Circulating Tumor DNA. Oncologist, 2019, 24, 1022-1026.	1.9	16
98	A Phase II Study of Osimertinib Combined With Platinum Plus Pemetrexed in Patients With EGFR-Mutated Advanced Nonâ€“Small-cell Lung Cancer: The OPAL Study (NEJ032C/LOGIK1801). Clinical Lung Cancer, 2021, 22, 147-151.	1.1	16
99	PICT1 expression is a poor prognostic factor in non-small cell lung cancer. Oncoscience, 2014, 1, 375-382.	0.9	16
100	Visualization and quantitation of epidermal growth factor receptor homodimerization and activation with a proximity ligation assay. Oncotarget, 2017, 8, 72127-72132.	0.8	14
101	Combined therapy with epidermal growth factor receptor tyrosine kinase inhibitors for nonâ€“small cell lung cancer. Expert Review of Anticancer Therapy, 2018, 18, 267-276.	1.1	14
102	Phase I/II study of carboplatin plus nab-paclitaxel and concurrent radiotherapy for patients with locally advanced nonâ€“small cell lung cancer. Lung Cancer, 2018, 125, 136-141.	0.9	14
103	Differential significance of molecular subtypes which were classified into EGFR exon 19 deletion on the first line afatinib monotherapy. BMC Cancer, 2020, 20, 103.	1.1	14
104	Paired genetic analysis by nextâ€generation sequencing of lung cancer and associated idiopathic pulmonary fibrosis. Cancer Science, 2020, 111, 2482-2487.	1.7	14
105	A Randomized Phase II Study Comparing Nivolumab With Carboplatin-Pemetrexed for Patients With EGFR Mutationâ€“Positive Nonsquamous Nonâ€“Small-Cell Lung Cancer Who Acquire Resistance to Tyrosine Kinase Inhibitors Not Due to a Secondary T790M Mutation: Rationale and Protocol Design for the WJOG8515L Study. Clinical Lung Cancer, 2017, 18, 719-723.	1.1	13
106	Integrated Immunohistochemical Study on Small-Cell Carcinoma of the Lung Focusing on Transcription and Co-Transcription Factors. Diagnostics, 2020, 10, 949.	1.3	13
107	Increased plasma levels of damage-associated molecular patterns during systemic anticancer therapy in patients with advanced lung cancer. Translational Lung Cancer Research, 2021, 10, 2475-2486.	1.3	13
108	Hypermethylation of the CpG dinucleotide in epidermal growth factor receptor codon 790: implications for a mutational hotspot leading to the T790M mutation in nonâ€“small-cell lung cancer. Cancer Genetics, 2015, 208, 271-278.	0.2	12

#	Article	IF	Citations
109	Sensitivity of epidermal growth factor receptor with single or double uncommon mutations to afatinib confirmed by a visual assay. Cancer Science, 2018, 109, 3657-3661.	1.7	12
110	Survival Analysis for Patients with ALK Rearrangement-Positive Non-Small Cell Lung Cancer and a Poor Performance Status Treated with Alectinib: Updated Results of Lung Oncology Group in Kyushu 1401. Oncologist, 2020, 25, 306-e618.	1.9	12
111	Treatment Rationale and Design for APPLE (WJOG11218L): A Multicenter, Open-Label, Randomized Phase 3 Study of Atezolizumab and Platinum/Pemetrexed With or Without Bevacizumab for Patients With Advanced Nonsquamous Nonâ€“Small-Cell Lung Cancer. Clinical Lung Cancer, 2020, 21, 472-476.	1.1	12
112	Predicting osimertinibâ€treatment outcomes through EGFR mutantâ€fraction monitoring in the circulating tumor DNA of EGFR T790Mâ€positive patients with nonâ€small cell lung cancer (WJOG8815L). Molecular Oncology, 2021, 15, 126-137.	2.1	12
113	A Multicenter, Randomized Phase III Study Comparing Platinum Combination Chemotherapy Plus Pembrolizumab With Platinum Combination Chemotherapy Plus Nivolumab and Ipilimumab for Treatment-Naive Advanced Nonâ€“Small Cell Lung Cancer Without Driver Gene Alterations: JCOG2007 (NIPPON Study). Clinical Lung Cancer, 2022, 23, e285-e288.	1.1	12
114	Characteristics of Smoking Patients with Lung Cancer with Emphysematous Bullae. Journal of Thoracic Oncology, 2016, 11, 1586-1590.	0.5	11
115	Prognostic Impact of PD-L2 Expression and Association with PD-L1 in Patients with Small-cell Lung Cancer. Anticancer Research, 2018, 38, 5903-5907.	0.5	11
116	Localized malignant pleural mesothelioma mimicking an anterior mediastinal tumor. European Journal of Radiology Open, 2019, 6, 72-77.	0.7	11
117	Randomized phase III study of pemetrexed/cisplatin (Pem/Cis) versus vinorelbine /cisplatin (Vnr/Cis) for completely resected stage II-IIIA non-squamous non-small-cell lung cancer (Ns-NSCLC): The JIPANG study.. Journal of Clinical Oncology, 2019, 37, 8501-8501.	0.8	11
118	Clinical development of nintedanib for advanced non-small-cell lung cancer. Therapeutics and Clinical Risk Management, 2015, 11, 1701.	0.9	10
119	Osimertinib in patients with epidermal growth factor receptor T790M advanced nonâ€small cell lung cancer selected using cytology samples. Cancer Science, 2018, 109, 1177-1184.	1.7	10
120	Randomized phase II study of pemetrexed or pemetrexed plus bevacizumab for elderly patients with previously untreated non-squamous non-small cell lung cancer: Results of the Lung Oncology Group in Kyushu (LOGIK1201). Lung Cancer, 2019, 132, 1-8.	0.9	10
121	Pemetrexed and carboplatin combination therapy followed by pemetrexed maintenance in Japanese patients with non-squamous non-small cell lung cancer: A subgroup analysis of elderly patients. Respiratory Investigation, 2019, 57, 27-33.	0.9	10
122	Expression of PD-L1, PD-L2, and IDO1 on tumor cells and density of CD8-positive tumor-infiltrating lymphocytes in early-stage lung adenocarcinoma according to histological subtype. Journal of Cancer Research and Clinical Oncology, 2020, 146, 2639-2650.	1.2	10
123	A propensity score-matched analysis of the impact of statin therapy on the outcomes of patients with non-small-cell lung cancer receiving anti-PD-1 monotherapy: a multicenter retrospective study. BMC Cancer, 2022, 22, 503.	1.1	10
124	CD44 variantâ€“dependent regulation of redox balance in EGFR mutationâ€“positive nonâ€“small cell lung cancer: A target for treatment. Lung Cancer, 2017, 113, 72-78.	0.9	9
125	Treatment Rationale and Design for J-AXEL: AÂRandomized Phase 3 Study Comparing Nab-Paclitaxel With Docetaxel in Patients With Previously Treated Advanced Nonâ€“Small-Cell Lung Cancer. Clinical Lung Cancer, 2017, 18, 100-103.	1.1	9
126	First-line durvalumab plus platinum-etoposide in extensive-stage small-cell lung cancer: CASPIAN Japan subgroup analysis. International Journal of Clinical Oncology, 2021, 26, 1073-1082.	1.0	9

#	Article	IF	Citations
127	Cytotoxic chemotherapeutic agents and the EGFR-TKI osimertinib induce calreticulin exposure in nonâ€“small cell lung cancer. Lung Cancer, 2021, 155, 144-150.	0.9	9
128	Antibiotic-dependent effect of probiotics in patients with non-small cell lung cancer treated with PD-1 checkpoint blockade. European Journal of Cancer, 2022, 172, 199-208.	1.3	9
129	A phase II study of Osimertinib for patients with radiotherapy-naÃ¯ve CNS metastasis of non-small cell lung cancer: treatment rationale and protocol design of the OCEAN study (LOGIK 1603/WJOG 9116L). BMC Cancer, 2020, 20, 370.	1.1	8
130	Randomized phase III study comparing carboplatin plus pemetrexed followed by pemetrexed versus docetaxel in elderly patients with advanced non-squamous non-small-cell lung cancer (JCOG1210/WJOG7813L).. Journal of Clinical Oncology, 2019, 37, 9031-9031.	0.8	8
131	Do infections with disseminated Mycobacterium avium complex precede sweet's syndrome? A case report and literature review. International Journal of Mycobacteriology, 2017, 6, 336.	0.3	8
132	The clinical impact of concomitant medicationÂuse on the outcome of postoperative recurrent non-small-cell lung cancer in patients receiving immune checkpoint inhibitors. PLoS ONE, 2022, 17, e0263247.	1.1	8
133	Severe Aplastic Anemia during Osimertinib TherapyÂin a Patient withÂEGFR Tyrosine KinaseÂInhibitorâ€“Resistant Nonâ€“Small Cell Lung Cancer. Journal of Thoracic Oncology, 2017, 12, e46-e47.	0.5	7
134	Immune Checkpoint Inhibitors for the Treatment of Unresectable Stage III Nonâ€“Small Cell Lung Cancer: Emerging Mechanisms and Perspectives . Lung Cancer: Targets and Therapy, 2020, Volume 10, 161-170.	1.3	7
135	Paired analysis of tumor mutation burden for lung adenocarcinoma and associated idiopathic pulmonary fibrosis. Scientific Reports, 2021, 11, 12732.	1.6	7
136	Safety analysis of an open label, randomized phase 2 study of osimertinib alone versus osimertinib plus carboplatin-pemetrexed for patients with nonâ€“small cell lung cancer (NSCLC) that progressed during prior epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy and which harbors a T790M mutation of EGFR.. Journal of Clinical Oncology, 2018, 36, e21073-e21073.	0.8	7
137	Phase I study of nintedanib in combination with pemetrexed as second-line treatment of Japanese patients with advanced non-small cell lung cancer. Cancer Chemotherapy and Pharmacology, 2015, 76, 1225-1233.	1.1	6
138	Successful treatment with alectinib after crizotinib-induced esophageal ulceration. Lung Cancer, 2015, 88, 349-351.	0.9	6
139	Survival and prognostic factors in elderly patients receiving second-line chemotherapy for relapsed small-cell lung cancer: Results from the Japanese Joint Committee of Lung Cancer Registry. Lung Cancer, 2020, 146, 160-164.	0.9	6
140	A Phase II Study to Assess the Efficacy of Osimertinib in Patients With EGFR Mutation-positive NSCLC Who Developed Isolated CNS Progression (T790M-negative or Unknown) During First- or Second-generation EGFR-TKI or Systemic Disease Progression (T790M-negative) After Treatment With First- or Second-generation EGFR-TKI and Platinum-based Chemotherapy (WJOG12819L). Clinical Lung Cancer, 2021, 22, 376-380.	1.1	6
141	Firstâ€line pembrolizumab vs chemotherapy in metastatic nonâ€smallâ€cell lung cancer: KEYNOTEâ€024 Japan subset*. Cancer Science, 2021, 112, 5000-5010.	1.7	6
142	Influence of dose adjustment on afatinib safety and efficacy in patients (pts) with advanced EGFR mutation-positive (EGFRm+) non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2015, 33, 8073-8073.	0.8	6
143	Atezolizumab for Pretreated Non-Small Cell Lung Cancer with Idiopathic Interstitial Pneumonia: Final Analysis of Phase II AMBITIOUS Study. Oncologist, 2022, 27, 720-e702.	1.9	6
144	Beau's Lines and Mees' Lines Formations after Chemotherapy. Internal Medicine, 2015, 54, 2281-2281.	0.3	5

#	Article	IF	Citations
145	Multiple regulatory mechanisms of hepatocyte growth factor expression in malignant cells with a short poly(dA) sequence in the HGF gene promoter. Oncology Letters, 2015, 9, 405-410.	0.8	5
146	Association between peripheral blood markers and immune-related factors on tumor cells in patients with resected primary lung adenocarcinoma. PLoS ONE, 2019, 14, e0217991.	1.1	5
147	Predictive and prognostic impact of primary tumorâ€bearing lobe in nonsmall cell lung cancer patients treated with antiâ€PD â€1 therapy. International Journal of Cancer, 2020, 147, 2327-2334.	2.3	5
148	Remarkable response to dacomitinib in a patient with leptomeningeal carcinomatosis due to EGFR â€mutant nonâ€small cell lung cancer. Thoracic Cancer, 2021, 12, 114-116.	0.8	5
149	Rationale and Design for a Multicenter, Phase II Study of Durvalumab Plus Concurrent Radiation Therapy in Locally Advanced Non-Small Cell Lung Cancer: The DOLPHIN Study (WJOG11619L). Cancer Management and Research, 2021, Volume 13, 9167-9173.	0.9	5
150	Erlotinib with or without bevacizumab as a firstâ€line therapy for patients with advanced nonsquamous epidermal growth factor receptorâ€positive nonâ€small cell lung cancer: Exploratory subgroup analyses from the phase <scp>II JO25567</scp> study. Thoracic Cancer, 2022, 13, 2192-2200.	0.8	5
151	A Phase I Study of Split-dose Cisplatin and Etoposide with Concurrent Accelerated Hyperfractionated Thoracic Radiotherapy in Elderly Patients with Limited-disease Small Cell Lung Cancer. Japanese Journal of Clinical Oncology, 2014, 44, 743-748.	0.6	4
152	Meta-analysis of pemetrexed plus carboplatin doublet safety profile in first-line non-squamous non-small cell lung cancer studies. Current Medical Research and Opinion, 2017, 33, 937-941.	0.9	4
153	Chronic myelomonocytic leukemia blast crisis in a patient with advanced non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors. Respiratory Investigation, 2017, 55, 181-183.	0.9	4
154	Radiological Features of Programmed Cell Death-Ligand 2-positive Lung Adenocarcinoma: A Single-institution Retrospective Study. In Vivo, 2018, 32, 1541-1550.	0.6	4
155	Japanese subgroup analysis of a phase III study of S-1 versus docetaxel in non-small cell lung cancer patients after platinum-based treatment: EAST-LC. International Journal of Clinical Oncology, 2019, 24, 485-493.	1.0	4
156	Updated Survival Data for a Phase I/II Study of Carboplatin plus Nabâ€Paclitaxel and Concurrent Radiotherapy in Patients with Locally Advanced Nonâ€Small Cell Lung Cancer. Oncologist, 2020, 25, 475.	1.9	4
157	Therapies after first-line afatinib in patients with EGFRm⁺ NSCLC in Japan: retrospective analysis of LUX-Lung 3. Future Oncology, 2020, 16, 49-60.	1.1	4
158	Multiclonality and Radiosensitivity of Granulocyte-colony Stimulating Factor-Producing Lung Adenocarcinoma Positive for an Activating EGFR Mutation. Clinical Lung Cancer, 2020, 21, e21-e24.	1.1	4
159	Nivolumab treatment of elderly Japanese patients with non-small cell lung cancer: subanalysis of a real-world retrospective observational study (CA209-9CR). ESMO Open, 2020, 5, e000656.	2.0	4
160	Association of Mps one binder kinase activator 1 (<scp>MOB1)</scp> expression with poor diseaseâ€free survival in individuals with nonâ€small cell lung cancer. Thoracic Cancer, 2020, 11, 2830-2839.	0.8	4
161	Quantification of HER family dimers by proximity ligation assay and its clinical evaluation in nonâ€“small cell lung cancer patients treated with osimertinib. Lung Cancer, 2021, 158, 156-161.	0.9	4
162	Identification of Genomic Alterations Acquired During Treatment With EGFR-TKIs in Non-small Cell Lung Cancer. Anticancer Research, 2019, 39, 671-677.	0.5	4

#	Article	IF	Citations
163	Phase II Study of Nivolumab Plus Ipilimumab with Platinum-Based Chemotherapy for Treatment-NaÃ¯ve Advanced Non-Small Cell Lung Cancer with Untreated Brain Metastases: NIke Trial (LOGiK2004). Cancer Management and Research, 2021, Volume 13, 8489-8493.	0.9	4
164	ANtiangiogenic Second-line Lung cancer Meta-Analysis on individual patient data in non-small cell lung cancer: ANSELMA. European Journal of Cancer, 2022, 166, 112-125.	1.3	4
165	A phase II study of durvalumab (MEDI4736) immediately after completion of chemoradiotherapy in unresectable stage III nonâ€“small cell lung cancer: TORG1937 (DATE study).. Journal of Clinical Oncology, 2022, 40, 8536-8536.	0.8	4
166	Current status and future perspectives of cooperative study groups for lung cancer in Japan. Respiratory Investigation, 2014, 52, 339-347.	0.9	3
167	Association of nephrotoxicity during platinum-etoposide doublet therapy with UGT1A1 polymorphisms in small cell lung cancer patients. Lung Cancer, 2018, 126, 156-161.	0.9	3
168	Immune checkpoint protein and cytokine expression by T lymphocytes in pleural effusion of cancer patients receiving antiâ€“PD-1 therapy. Lung Cancer, 2019, 138, 58-64.	0.9	3
169	Scedosporium apiospermum lung disease in a patient with nontuberculous mycobacteria. Respirology Case Reports, 2021, 9, e00691.	0.3	3
170	A randomized phase III study of continuous maintenance bevacizumab with or without pemetrexed after induction therapy with carboplatin (Car), pemetrexed (Pem), and bevacizumab (Bev) for advanced non-squamous non-small cell lung cancer (nSQ-NSCLC) without sensitizing EGFR mutations: The COMPASS study (WJOG5610L).. Journal of Clinical Oncology, 2019, 37, 9003-9003.	0.8	3
171	A multicenter, open label, randomized phase III study of atezolizumab with platinum-pemetrexed and with or without bevacizumab for patients with advanced nonsquamous non-small cell lung cancer (WJOG11218L APPLE Study).. Journal of Clinical Oncology, 2019, 37, TPS9125-TPS9125.	0.8	3
172	HTLVâ€1 seropositive patients with lung cancer treated with PDâ€1 inhibitors. Cancer Science, 2020, 111, 3395-3396.	1.7	2
173	A randomized phase 3 study of maintenance therapy with Sâ€1 plus best supportive care versus best supportive care after induction therapy with carboplatin plus Sâ€1 for advanced or relapsed squamous cell carcinoma of the lung (WJOG7512L). Cancer, 2020, 126, 3648-3656.	2.0	2
174	Osimertinib-induced Syndrome of Inappropriate Secretion of Antidiuretic Hormone. Clinical Lung Cancer, 2021, 22, e784-e785.	1.1	2
175	Phase I study on preliminary safety and efficacy of rovalpituzumab tesirine in Japanese patients (pts) with advanced, recurrent small cell lung cancer (SCLC).. Journal of Clinical Oncology, 2019, 37, 8557-8557.	0.8	2
176	Efficacy of platinum agents for stage III non-small-cell lung cancer following platinum-based chemoradiotherapy: a retrospective study. BMC Cancer, 2022, 22, 342.	1.1	2
177	Radiation-induced sarcoma in a 10-year survivor with stage IV EGFR-mutated lung adenocarcinoma. Respiratory Medicine Case Reports, 2019, 28, 100889.	0.2	1
178	Prognostic impact of primary cancer adjoining emphysematous bullae in non-small cell lung cancer patients treated with immune checkpoint inhibitors. Cancer Immunology, Immunotherapy, 2021, 70, 1745-1753.	2.0	1
179	A longâ€term survivor keeping in a complete response without treatment after pemetrexed maintenance therapy for advanced nonâ€squamous nonâ€small cell lung cancer. Clinical Case Reports (discontinued), 2021, 9, 927-931.	0.2	1
180	A phase II study of osimertinib in combination with platinum plus pemetrexed in patients with EGFR-mutated, advanced nonâ€“small cell lung cancer: The OPAL study (NEJ032C/LOGIK1801).. Journal of Clinical Oncology, 2022, 40, 9097-9097.	0.8	1

#	Article	IF	Citations
181	Falciparum Malaria Incidentally Pretreated with Azithromycin. Internal Medicine, 2015, 54, 2513-2516.	0.3	0
182	Metastatic Lung Adenocarcinoma Mimicking Meningioma. Internal Medicine, 2018, 57, 1057-1058.	0.3	0
183	Mondor's Disease of the Chest Wall. Internal Medicine, 2019, 58, 3349-3349.	0.3	0
184	Albumin-bilirubin grade as a significant prognostic factor in patients with non-small cell lung cancer treated with anti-PD-1-based therapy: A multicenter retrospective study.. Journal of Clinical Oncology, 2021, 39, e21125-e21125.	0.8	0
185	Multiplex genomic profiling of non-small cell lung cancer patients enrolled in the LETS phase III trial of first-line S-1/carboplatin versus paclitaxel/carboplatin (WJOG6611LTR).. Journal of Clinical Oncology, 2014, 32, 8095-8095.	0.8	0
186	Pooled safety analysis of EGFR-TKI therapy in patients with EGFR-mutated non-small cell lung cancer.. Journal of Clinical Oncology, 2014, 32, e19078-e19078.	0.8	0
187	Bevacizumab beyond disease progression after first-line treatment with bevacizumab plus chemotherapy inadvanced nonsquamous nonâ€“small cell lung cancer (WJOG 5910L): An open-label, randomized, phase II trial.. Journal of Clinical Oncology, 2015, 33, 8056-8056.	0.8	0
188	Overall survival (OS) of EGFR mutation-positive non-small cell lung cancer (NSCLC) patients: Real-world treatment patterns of 1,660 Japanese patients (pts).. Journal of Clinical Oncology, 2016, 34, e20503-e20503.	0.8	0
189	Predictive impact of complete molecular response in plasma: A phase II, liquid biopsy study in EGFR mutated NSCLC patients treated with afatinib (WJOG 8114LTR).. Journal of Clinical Oncology, 2017, 35, 9027-9027.	0.8	0
190	5. Current Potential and Clinical Questions of Immune Checkpoint Inhibitors in the Treatment of Advanced Non-small Cell Lung Cancer. The Journal of the Japanese Society of Internal Medicine, 2017, 106, 1117-1124.	0.0	0
191	The impact of sequential therapy of crizotinib followed by alectinib: Real-world data analysis of 840 ALK-inhibitor naÃ¯ve patients with NSCLC harboring ALK-rearrangement (WJOG9516L).. Journal of Clinical Oncology, 2019, 37, 9038-9038.	0.8	0
192	Updated survival date of phase I/II study of carboplatin plus nab-paclitaxel and concurrent radiotherapy for patients with locally advanced non-small cell lung cancer.. Journal of Clinical Oncology, 2019, 37, 8529-8529.	0.8	0
193	Randomized phase 3 study of maintenance therapy with S-1 plus best supportive care (BSC) versus BSC alone after induction therapy with carboplatin plus S-1 for advanced or relapsed squamous cell lung carcinoma (WJOG7512L).. Journal of Clinical Oncology, 2019, 37, e20531-e20531.	0.8	0
194	Molecularly-targeted Therapies for Advanced Non-small-cell Lung Cancer. Japanese Journal of Lung Cancer, 2019, 59, 1115-1118.	0.0	0
195	Molecularly-targeted Therapies for Advanced Non-small-cell Lung Cancer. Japanese Journal of Lung Cancer, 2020, 60, 877-880.	0.0	0
196	Predictive model of the prognosis in non-small cell lung cancer treated with first-line immunotherapy based on machine learning.. Journal of Clinical Oncology, 2022, 40, e21125-e21125.	0.8	0